Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
Exploring ketamine’s potential in the fight against treatment-resistant depression
- Post author:admin
- Post published:February 19, 2025
- Post category:uncategorized